MYO - Myomo, Inc.
| Previous Close | 1.2600 |
| Open | 1.2400 |
| Bid | 1.2500 x 1800 |
| Ask | 1.2800 x 1800 |
| Day's Range | 1.2500 - 1.2836 |
| 52 Week Range | 1.1500 - 4.3000 |
| Volume | 52,229 |
| Avg. Volume | 98,101 |
| Market Cap | 21.527M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8390 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
- Business Wire•4 days ago
Myomo® Announces New Sales and Service Agreement for Italy
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has signed an agreement with Progettiamo Autonomia Robotics (PAR) with the goal of offering MyoPro in Italy. PAR is a unit of Progettiamo Autonomia, headquartered in Reggio Emilia, Italy, with 17 offices nationwide.
- Business Wire•7 days ago
Myomo Makes NYSE American Section 610(b) Public Announcement
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2018 filed on March 12, 2019 with the Securities and Exchange Commission, the audited financial statements for the year ended December 31, 2018 included in the 10-K contained an audit opinion from its independent registered public accounting firm, which included a going concern emphasis of matter paragraph. This announcement is made pursuant to NYSE American Company Guide Section 610(b), which requires separate public announcement of the receipt of an audit opinion containing a going concern paragraph.
- Simply Wall St.•11 days ago
What Should Investors Know About Myomo, Inc.’s (NYSEMKT:MYO) Future?
The latest earnings announcement Myomo, Inc. (NYSEMKT:MYO) released in December 2018 revealed that losses became smaller relative to the prior year's level - great news for investors Below is myRead More...
- Business Wire•11 days ago
Myomo Announces Participation at Two Upcoming Investor Conferences
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that Chairman and Chief Executive Officer Paul R. Gudonis and Chief Financial Officer David Henry will be presenting, as well as meeting with investors, at two upcoming investor conferences.
- Business Wire•15 days ago
Myomo Reports Fourth Quarter and Year End 2018 Results
Reports Record Revenues and Reimbursement Pipeline for the Fourth Quarter and Full Year
- ACCESSWIRE•15 days ago
Myomo, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 7, 2019 / Myomo, Inc. (NYSE MKT: MYO ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 7, 2019 at 4:30 PM Eastern Time. ...
- Business Wire•22 days ago
Myomo to Report Fourth Quarter and Year End 2018 Results on March 7, 2019
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2018 on Thursday, March 7, 2019, after the US markets close. The Company will host a conference call on Thursday, March 7, 2019 at 4:30 p.m. EST featuring remarks by Paul R. Gudonis, Chairman and Chief Executive Officer, and David Henry, Chief Financial Officer.
- GlobeNewswire•last month
Investor Expectations to Drive Momentum within Enphase Energy, EQT, BorgWarner, Ringcentral, Chanticleer, and Myomo — Discovering Underlying Factors of Influence
NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•last month
Myomo, Inc. Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today has closed its previously announced underwritten public offering of 3,950,000 shares of common stock at an offering price of $1.40 per share. In connection with the offering, the underwriter exercised in full its over-allotment option to purchase an additional 592,500 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock were offered by the Company.
- Business Wire•last month
Myomo, Inc. Prices Public Offering of Common Stock
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced the pricing of its previously announced underwritten public offering of 3,950,000 shares of its common stock at an offering price of $1.40 per share. The Company expects to receive gross proceeds from the offering of approximately $5.5 million, excluding underwriting discounts and commissions and other offering-related expenses and excluding any exercise of the over-allotment option. If the underwriter exercises its over-allotment option in full, gross proceeds from the offering would be approximately $6.4 million, excluding underwriting discounts and commissions and other offering-related expenses.
- Business Wire•last month
Myomo, Inc. Announces Proposed Public Offering of Common Stock
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Myomo expects to grant the underwriter a 45-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. All of the shares of common stock are being offered by the Company.
- Business Wire•last month
Myomo Announces CFO Succession
Myomo Inc. (NYSE American MYO) (“Myomo,” or the “Company”), a wearable medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis, today announced that Ralph A. Goldwasser, its Chief Financial Officer, is retiring effective as of February 18, 2019. Mr. Goldwasser, age 71, will provide transitional services to the Company for an expected three-month term under a transition and consulting agreement. He will be succeeded by David Henry, effective February 18, 2019.
- Business Wire•2 months ago
Myomo® to Present at Noble Capital Markets’ 15th Annual Investor Conference
Myomo, Inc. , a wearable medical robotics company, today announced that it will be presenting at NobleCon15 - Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida on Monday, January 28th at 10:30 AM EST - Studio 3.
- Business Wire•4 months ago
Myomo Announces First Adolescent Patients to be Fitted with MyoPro
Myomo, Inc., a wearable medical robotics company, has achieved recent momentum fitting and delivering MyoPro to adolescent users. Approved to assist young adults suffering from any disease or injury leaving them with a paralyzed or weakened arm, MyoPro is restoring motion and functionality to adolescents with conditions such as cerebral palsy, brachial plexus injury, and more. MyoPro is now being tested on Acute Flaccid Myelitis ("AFM") patients with promising results.
- GlobeNewswire•4 months ago
Analysis: Positioning to Benefit within Noble Energy, Myomo, Realty Income, Cross Country Healthcare, Ares Management, and Archrock — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 07, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•4 months ago
Myomo® Receives Medicare Codes
Myomo, Inc. (NYSE American: MYO) (“Myomo,” or the “Company”), a wearable medical robotics company, announces that the Centers for Medicare & Medicaid Services ("CMS") has published two new codes pursuant to the Company’s application for Healthcare Common Procedure Coding System (HCPCS) “L” codes. Myomo had filed its application in December 2017 to have CMS establish two new Level II HCPCS codes and received a favorable preliminary decision in May.
- Zacks•5 months ago
Myomo, Inc. (MYO) Reports Q3 Loss, Misses Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -5.00% and -25.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire•5 months ago
Myomo Announces Third Quarter 2018 Financial Results
Achieved Revenue Growth of 25% and Reported 222 units in the Reimbursement Process
- Business Wire•5 months ago
Myomo to Report Third Quarter 2018 Results on November 5, 2018
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company, today announced that it will release its financial results for the third quarter 2018 on Monday, November 5, 2018, after the US markets close. The Company will host a conference call on Monday, November 5, 2018 at 4:30 p.m. EST featuring remarks by Paul R. Gudonis, Chairman and Chief Executive Officer, and Ralph A. Goldwasser, Chief Financial Officer. The conference call, webcast and accompanying slides can be accessed through Myomo’s Investor Relations page.
- Zacks•5 months ago
Myomo, Inc. (MYO) Q3 Earnings Preview: What to Look Out For
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.•5 months ago
Are Myomo Inc’s (NYSEMKT:MYO) Interest Costs Too High?
The direct benefit for Myomo Inc (NYSEMKT:MYO), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off is Read More...
- Simply Wall St.•6 months ago
Do Institutions Own Shares In Myomo Inc (NYSEMKT:MYO)?
The big shareholder groups in Myomo Inc (NYSEMKT:MYO) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a Read More...
- ACCESSWIRE•6 months ago
Myomo to Present at The MicroCap Conference
/ ACCESSWIRE / September 18, 2018 / Myomo, Inc. (NYSE American: MYO) ("Myomo" or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will be presenting at The MicroCap Conference on Monday, October 1st at 11:00 AM EDT, Track 1, Essex House in New York City. Chairman and Chief Executive Officer Paul R. Gudonis and Chief Financial Officer Ralph A. Goldwasser will be presenting, as well as meeting with investors. A webcast of the presentation will be available at the Investor Relations page of the Company's website.
- IPO Edge•9 months ago
One Year into Reg A+ IPOs, Investment Banker Predicts New Class of Securities to Drive Growth
Mark Elenowitz Says Security Token Offerings May Thrive via Reg A+ We recently sat down for lunch in Manhattan with Mark Elenowitz, CEO of TriPoint Global Equities, to discuss the anniversary of the IPO of Myomo, a wearable medical products company that he took public in the first Reg A+ deal to list on a […]
